-
The place issued a document requiring pharmacies to implement "zero-markup" sales of centralized procurement products
Time of Update: 2022-08-20
It is worth mentioning that under the background that Jiangsu Province vigorously promotes pharmacies to implement "zero-markup" sales of centrally-purchased products, the first batch of "medical insurance convenience pharmacies" in Xuzhou has been built recently, and 23 pharmacies have passed the inspection and were officially listed.
-
There is a reduction and an increase in holdings. Is CRO still worth looking forward to?
Time of Update: 2022-08-20
In addition, the performance of Haite Bio, Zhaoyan New Drug, WuXi AppTec, and Kyushu Pharmaceuticals are also expected to achieve growth, with an increase of more than 20% in the first half of the year .
-
Two pharmaceutical companies announced acquisitions within 1 day, in order to expand their business scope and solve environmental problems
Time of Update: 2022-08-20
0659 million yuan Lukang Pharmaceutical: It plans to purchase 60% equity of Zhonghe Environmental Protection Company held by Hualu Group for 62.
0659 million yuan Lukang Pharmaceutical: It plans to purchase 60% equity of Zhonghe Environmental Protection Company held by Hualu Group for 62.
-
The ADC drug innovation war is about to break out!
Time of Update: 2022-08-20
Among them, Rongchang Bio and Genting Xinyao have ADC products approved for marketing; while the ADC products of Hengrui Medicine, Kelun Pharmaceutical, Innovent Bio, Huadong Medicine and other companies are already in Phase III clinical stage .
-
The brand of Dongcheng Pharmaceutical has been renewed and entered a new era of take-off and development
Time of Update: 2022-08-20
Dongcheng Orange/Stable Gray new image upgrade concept After more than 20 years of development, as a heparin expert and nuclear drug pioneer, Dongcheng Pharmaceutical's API business and nuclear drug business occupy an important position in the market .
-
The highest drop is 96.67%!
Time of Update: 2022-08-20
62%; duloxetine hydrochloride enteric-coated capsules (30mg calculated by C18H19NOS) decreased from 171 yuan / bottle dropped to 21.
62%; duloxetine hydrochloride enteric-coated capsules (30mg calculated by C18H19NOS) decreased from 171 yuan / bottle dropped to 21.
-
MNC's first half report card: Pfizer, Johnson & Johnson, Roche revenue TOP3!
Time of Update: 2022-08-20
6 billion, an increase of 19% year-on-year; the rare disease business grew rapidly, with total revenue reaching US$3.
6 billion, an increase of 19% year-on-year; the rare disease business grew rapidly, with total revenue reaching US$3.
-
In order to open up new markets, pharmaceutical machine companies are continuously increasing investment in innovative research and development
Time of Update: 2022-08-20
While the performance of pharmaceutical companies continues to improve, R&D investment is also increasing (Source: Pharmaceutical Network) While the performance of pharmaceutical companies continues to improve, R&D investment is also increasing While the performance of pharmaceutical companies continues to improve, R&D investment is also increasing On August 10, the 2022 semi-annual report released by Huadong Medicine showed that the company achieved operating income of 18.
-
Guangdong issues guidelines for the development of forest, grass and Chinese medicinal materials industry
Time of Update: 2022-08-20
The "Guidelines for the Development of Forest, Grass and Chinese Medicinal Materials Industry in Guangdong Province" proposes that Guangdong should take regional climate, soil and geographical environment conditions as the basic elements, take the distribution of forest land resources and community characteristics as important conditions, and take regional socio-economic levels and historically formed conditions.
-
Menarini Group's drug elastrant has been granted priority review status by the FDA
Time of Update: 2022-08-20
About the Phase 3 study of elasitran (RAD1901) and EMERALD Elastrant is an investigational selective estrogen receptor degrader (SERD) currently being evaluated as a once-daily oral treatment for patients with ER+/HER2- advanced or metastatic breast cancer .
-
Many large tertiary hospitals purchase "do not accept imported products"!
Time of Update: 2022-08-19
Consumables have made imported products experience a huge impact on price:In addition to the centralized procurement of medical device consumables, the original research formed by the centralized procurement of national drugs with a large amount of drugs is gradually included in the scope of centralized procurement of drugs with "large clinical dosage and high procurement amount", covering all kinds of drugs that are clinically necessary and of reliable quality and are marketed in China.
-
The ADC drug market is surging, and the innovation battle will be unveiled!
Time of Update: 2022-08-19
As of July this year, Kelun Pharmaceutical and CSPC announced within 3 days that two ADC drugs (ie antibody-drug conjugates) were authorized to Merck and an American biopharmaceutical company respectively, with a total transaction value of more than 2 billion US dollars .
-
Notice on holding a training course on research and exchange of key quality attributes of pharmaceutical excipients
Time of Update: 2022-08-19
All relevant units: With the deepening of the related review of pharmaceutical excipients and preparations, the focus on key quality attributes of pharmaceutical excipients in the entire life cycle o
-
Overseas institutions researched more than 60 listed companies, focusing on electronics, power equipment, medicine and biology and other industries
Time of Update: 2022-08-19
In the past 10 days, a total of 7 listed pharmaceutical and biological companies have received the attention of overseas institutions, including Jiudian Pharmaceutical, Changchun High-tech, Walter Dyne, Weiss Medical, Weili Medical, etc.
-
The enthusiasm for the research and development of new Chinese medicines is high, and many pharmaceutical companies have submitted clinical applications since the second half of the year!
Time of Update: 2022-08-19
At the same time, the Blue Book pointed out that in recent years, the ability of traditional Chinese medicine to inherit and innovate has been significantly enhanced, and the number of applications for new Chinese medicine clinical trials and new drug marketing authorization applications has increased year by year .
-
In order to enter the medical insurance, this drug with an annual cost of more than 1 million yuan is reduced to less than 500,000 yuan!
Time of Update: 2022-08-19
On August 8, Heilongjiang Province announced the list of drugs that companies applied for price reduction in July, including ripatinib, which has an annual cost of over one million yuan .
-
The import of sagebrush has decreased, and the long-term will continue to be optimistic!
Time of Update: 2022-08-19
chinensis supplies the market with wild sources, and mainly imported goods.
chinensis supplies the market with wild sources, and mainly imported goods.
chinensis supplies the market with wild sources, and mainly imported goods.
chinensis supplies the market with wild sources, and mainly imported goods.
-
Several vaccination centres in Hong Kong increase vaccination services for young children
Time of Update: 2022-08-19
Children's Hospital Yang Hebei Yin said after inspecting the two vaccination centers that only vaccination against the new crown can reduce the risk of severe illness, death or serious sequelae after infection.
-
Multinational pharmaceutical companies accelerate their deployment in China, and another new drug is approved for clinical use
Time of Update: 2022-08-19
[Pharmaceutical Network Industry News] On August 16, the website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of the People's Republic of China showed that Merck's Class 1 new drug MK-4830 injection has obtained an implied license for clinical trials and is intended to be developed for use in Treatment of advanced solid tumors .
-
Two departments: Strictly prohibit discrimination against workers such as those who have recovered from COVID-19
Time of Update: 2022-08-19
According to the Labor Law, the Employment Promotion Law, the Infectious Disease Prevention Law and other laws and regulations, employers who recruit personnel and human resources service agencies to engage in occupational intermediary activities shall not discriminate against workers such as those who have recovered from COVID-19 .
